HJFMRI supports the Kenya Medical Research Institute (KEMRI) in clinical research to test and advance malaria vaccines.
Most recently, the Mal 094 study was conducted in Western Kenya as a Phase 2b trial to study the efficacy, safety and immunogenicity of the world’s first malaria vaccine, RTS,S/AS01E. HJFMRI provided day-to-day research operations support for this malaria vaccine research and ensured safe, uninterrupted continuance of research in the face of COVID-related challenges and restrictions.
CASE STUDY: In Search of a Malaria Vaccine Despite the COVID-19 Pandemic
To prevent the COVID-19 pandemic from completely disrupting a malaria vaccine trial, the HJFMRI team developed innovative and efficient methods to support the day-to-day clinical study operations.